Notes from the Lab: Novel targets for immune checkpoint inhibitors
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
09/17/2023
Notes from the Lab: Novel targets for immune checkpoint inhibitors
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory Survival rates of patients with melanoma have drastically improved in the…
|
08/15/2023
Clinical Trials Catch Up
Welcome to our new interview series called Clinical Trials Catch Up, an article delivered in a question-and-answer format designed to…
|
08/01/2023
AIM’s Latest Newsletter: The Research Edition, July 2023
This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research. This edition features: Letter from AIM’s…
|
05/30/2023
Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma
May 26, 2023 17:30 ET| Source: Iovance Biotherapeutics, Inc. Priority Review Granted with Prescription Drug User Fee Act (PDUFA) Action Date…
|
|
02/28/2023
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application and European Medicines Agency Validates Application for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
February 28, 2023 | Source: PRINCETON, N.J.–(BUSINESS WIRE)– The applications are based on results from the Phase 3 CheckMate -76K trial,…
|
|
01/27/2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
|
01/26/2023
A Letter From Our Vice President | January 2023
Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
|
01/26/2023
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
|
01/26/2023
What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
|
12/08/2022
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
|
|
Entradas recientes
Sep. 17, 2023
Notes from the Lab: Novel targets for immune checkpoint inhibitors
Sep. 12, 2023
Becoming a Melanoma Caregiver…Now What? PART III with guest host, Melissa Wilson, PA-C, MPAS, UPMC Hillman Cancer Center
Sep. 07, 2023
In Plain English—Neoadjuvant Therapy for Melanoma, and How We Got Here
Aug. 28, 2023
Survivor Profile: Tricia Riffenburgh, Stage IV Melanoma
Aug. 15, 2023